Skip to main content

Advertisement

SpringerLink
Log in

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. French National Authority for Health - Haute Autorité de santé (HAS). Flutemetamol (VIZAMYL) - Transparency Committee [Internet]. 2022. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-19717_VIZAMYL_PIC_INS_Avisdef_CT19717.pdf. Accessed 25 Aug 2022.

  2. Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s Disease. J Alzheimers Dis. 2018;63:783–96.

    Article  Google Scholar 

  3. Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377–85.

    Article  CAS  Google Scholar 

  4. French National Authority for Health - Haute Autorité de santé (HAS).  Florbetapir (AMYVID) - Transparency Committee [Internet]. 2013. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-12957_AMYVID_PIC_INS_Avis3_CT12957.pdf. Accessed 25 Aug 2022.

  5. French National Authority for Health - Haute Autorité de santé (HAS). Florbetaben (NEURACEQ) - Transparency Committee [Internet]. 2019. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-01/neuraceq_pic_ins_avis3_ct16710.pdf. Accessed 25 Aug 2022.

  6. French National Authority for Health - Haute Autorité de santé (HAS) (2017) Flutemetamol (VIZAMYL) - Transparency Committee.

  7. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286.

    Article  Google Scholar 

  8. Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, et al. Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD Diagnostic and Patient Management Study. Alzheimers Dement [Internet]. 2022. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12696. Accessed 25 Aug 2022.

  9. NCT04426539. New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Care [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04426539. Accessed 25 Aug 2022.

  10. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Research Memory Center of Lyon, Lyon Institute For Aging, 27 Rue Gabriel Péri, 69100, Villeurbanne, France

    Antoine Garnier-Crussard

  2. Lyon Neuroscience Research Center, UMR5292, INSERM U1028/CNRS, Lyon, France

    Antoine Garnier-Crussard & Anthime Flaus

  3. Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France

    Anthime Flaus

Authors
  1. Antoine Garnier-Crussard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthime Flaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoine Garnier-Crussard.

Ethics declarations

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Letter to the Editor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garnier-Crussard, A., Flaus, A. Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol). Eur J Nucl Med Mol Imaging 50, 253–254 (2023). https://doi.org/10.1007/s00259-022-06025-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-022-06025-y

Search

Navigation